key trial updates in serds in er /her2- breast cancer from sabcs 2022
Published 1 year ago • 147 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
0:55
key highlights from sabcs 2022
-
0:51
sabcs 2022: key highlights
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
1:16
key data at sabcs 2022
-
1:03
key takeaways from sabcs 2022
-
2:57
key data from the san antonio breast cancer symposium (sabcs) 2022
-
2:56
key clinical trials in breast cancer presented at sabcs 2021
-
4:08
sabcs 2022 highlights
-
1:25
sabcs 2022: clinical trial highlights
-
2:35
what does the future hold for serds in er breast cancer?
-
2:16
sabcs 2022: destiny-breast02 destiny-breast03
-
1:06
sabcs 2022 highlights
-
0:36
maintenance w/ et ribociclib after 1l chemotherapy in hr /her2- metastatic breast cancer
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
2:00
sabcs 2022 takeaways
-
1:24
key trial updates from sabcs 2020
-
6:54
key clinical trials investigating immunotherapy in her2 and hr breast cancer